The U.S. Food and Drug Administration on Nov. 18 approved Infilbray (venglustat) tablets, the first treatment for the neurological symptoms of Type 3 Gaucher disease in adults and pediatric patients weighing at least 15 kilograms, or approximately 33 pounds. The agency said Infilbray crosses the blood-brain barrier to reduce the accumulation of harmful substances in the body and brain.
"For patients with Type 3 Gaucher disease, harmful substances build up in the brain without a way to stop them, but this drug's ability to cross the blood-brain barrier means it can get to the source of the buildup driving the neurological symptoms," said Acting FDA Commissioner Kyle Diamantas. "This approval reflects the FDA's commitment to advancing therapeutic options for patients with rare diseases and brings an important new treatment to patients and the healthcare providers who care for them." Type 3 Gaucher disease is a rare, inherited condition in which the body cannot properly break down fatty substances called glucosphingolipids because of a deficient or malfunctioning enzyme, the FDA said. As those substances accumulate in organs, tissues, and the brain, patients experience a wide range of serious health problems over time. Unlike type 1 Gaucher disease, type 3 also affects the brain and nervous system, causing difficulties with balance, coordination, speech, memory, and thinking, symptoms that can worsen progressively. Infilbray works as a glucosylceramide synthase inhibitor, reducing the buildup of harmful substances throughout the body and within the brain, the agency said.
The approval is supported by data from a randomized, double-blind, multicenter clinical study enrolling 43 patients aged 12 years and older with type 3 Gaucher disease who had previously been treated with enzyme replacement therapy and had achieved systemic disease stabilization. Participants received either Infilbray orally once daily or intravenous enzyme replacement therapy every two weeks for 52 weeks. Effectiveness was evaluated using two assessments that capture neurological symptoms central to daily life, including those related to ataxia, or loss of muscle control and coordination, and cognitive function. At week 52, patients treated with Infilbray demonstrated improvement on a measure that combined both assessments compared with those taking enzyme replacement therapy for the treatment of non-neurologic manifestations of the disease, the FDA said. The release does not publish a percentage improvement or a named score, and none is invented here.
The most frequently reported side effects include gastrointestinal symptoms as well as adverse effects on mood, the FDA said. Serious psychiatric risks, including suicidal ideation and behavior, have been reported. Potential risks identified from animal studies include potential clouding of vision in younger patients and adverse effects on fetal development when the drug is taken during pregnancy; the agency said more information on side effects can be found in the drug labeling. Infilbray was granted Orphan Drug designation as well as Priority Review. The approval was granted to Genzyme Corporation, a Sanofi company. This story reports the official Nov. 18 approval and labeled risks; it is not medical advice, and patients should rely on the FDA labeling and their clinicians.
